Phase 3 Trial eflapegrastim for Chemotherapy-Induced Neutropenia
Randomized, OpEn-Label, Active-ContrOl Trial of SPI-2012 (Eflapegrastim) Versus Pegfilgrastim in the Management of Chemotherapy-Induced Neutropenia in Early-Stage BReast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) (RECOVER)
*Eflapegrastim is an investigational drug not approved by the FDA.
Eflapegrastim is a long-acting form of G-CSF. Eflapegrastim (also known as HM10460A, Long Acting Protein/Peptide Discovery Platform Technology-G-CSF [LAPS-G-CSF]), is a chemically conjugated form of a modified G-CSF, being developed for reduction of the Duration of Severe Neutropenia (DSN) in patients with solid tumors and non-myeloid malignancies receiving myelosuppressive chemotherapy. Eflapegrastim is a biologic and not a biosimilar to either Neupogen (filgrastim) or Neulasta (pegfilgrastim).
If you would like to learn more about the Recover Phase 3 Study, please fill out the form below and one of our team will get back to you shortly.